2 active not recruiting, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
Follow zodasiran: new trials by email Literature Review of zodasiran trials Research Report on zodasiran
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Zodasiran - Homozygous Familial Hypercholesterolemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 10 | 2026-10-01 | 2026-10-26 |
| A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) zodasiran Injection, Placebo - Homozygous Familial Hypercholesterolemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 70 | 2025-06-17 | 2026-08-12 |
| A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients VSA003, Placebo - Homozygous Familial Hypercholesterolemia (HoFH) | Phase 3 | Active not recruiting | Visirna Therapeutics HK Limited | 46 | 2024-11-27 | 2026-05-05 |
Homozygous Familial Hypercholesterolemia (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dyslipidemias (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1)
Arrowhead Pharmaceuticals (2) · Visirna Therapeutics HK Limited (1)
United States (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Israel (1) · Japan (1) · New Zealand (1)
2025 (1)